DLBCL and Epcoritamab, A CD3xCD20 Bispecific ~ 8/4/22 @ 6PM

Thursday August 4th @ 6:00 pm

Atlantic Fish Co.

761 Boylston St, Boston, MA 02116

Presentation:

• DLBCL Overview

• Epcoritamab MOA (DuoBody® CD3xCD20)

• Epcoritamab in DLBCL

Thank you for your interest in attending this education program requested by Boston ONS.

Register Now

The presentation will be provided by the New England Genmab Medical Science Liaison on behalf of Genmab Medical Affairs.

Location: Atlantic Fish Company, 761 Boylston Street, Boston MA 02116

There are 18 slots available for this program and RSVP will secure your participation on a first-come-first-serve basis. Please RSVP by August 2nd, emailing arbi@genmab.com

at your earliest convenience, including your place of practice and current

professional role/credentials. Sign in will be required upon arrival. Please circulate this

invitation as you see fit keeping in mind that this program is intended for nurses, advanced practitioners, pharmacists, and physicians.

DISCLAIMER: Epcoritamab is currently under investigation for use in B-cell NHL. It is not

currently an FDA approved product. This non-promotional education program was requested by BONS and is being provided reactively.

Look forward to meeting you!

Arielle

Arielle Bibeault, PharmD, BCPS, BCOP

Senior Medical Science Liaison – New England

Based in Boston

Work Cell 609 613 2963 Personal Cell 401-323-8482

Genmab US, Inc. 777 Scudders Mill Road, Bldg. 2, 4th Floor, Plainsboro, NJ 08536, US